ETST Announces 60-Patient Clinical Prelaunch Study For Its MSN-2 Medical Device For The Diagnosis Of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aube As New CEO & CSO, And Nickolas Tabraue As President.
Ft. Lauderdale, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on hemp cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices; has announced that its wholly owned subsidiary, Earth Science Pharmaceutical, Inc., has initiated a clinical prelaunch study for its MSN-2 medical device for the diagnosis of Chlamydia and Gonorrhea in women. The study will involve 60 female patients. The company has also announced that it has elected Dr. Michel Aubé as its new CEO and CSO (Chief Scientific Officer), as well as Nickolas Tabraue as President of both Earth Science Tech, Inc., and its wholly-owned subsidiary Earth Science Pharmaceutical, Inc. This news follows the company's August 24, 2016 announcement, " ETST Acquired the Assets and Business of BEO-ITS, Inc., a Canadian Biotech Company Specializing in Medical Devices, Tests and Vaccines for Sexually Transmitted Infections and/or Diseases." This asset purchase agreement of BEO ITS, Inc., which was incorporated under ETST's new wholly-owned subsidiary, Earth Science Pharmaceutical, Inc., included the employment of its CEO and principal owner, Dr. Aubé as its CEO. "I'm honored and thrilled to be the CEO and CSO of both Earth Science Tech, Inc., and Earth Science Pharmaceutical, Inc., a company focused on the development of medical devices, testing processes, and vaccines for STIs (Sexually Transmitted Infections and/or Diseases)." stated Dr. Aubé. "I am also excited to announce that Earth Science Pharmaceutical has opened a clinical prelaunch study of its MSN-2 medical device for the diagnosis of Chlamydia and Gonorrhea which will allow us to acquire the final data we need to launch the product. I have personally been working with epidemiologist Dr. Lauren Azoulay on this new study, which will involve recruiting 20 women with Chlamydia and 40 women with Gonorrhea from private medical clinics for testing with our new MSN-2 medical device. The protocol, developed by Dr. Azoulay, will allow all physicians to understand the scope and the value of the new device. The protocol, with the results and the analyzed data, will be transmitted to the authorities once finished. This study will help Earth Science Pharmaceutical acquire all the necessary major regulatory approvals including; ISO 13485, FDA, and Health Canada. The results will be combined in a scientific report in the format of a Short Report or Rapid Communication and will be published in a selected scientific journal such the International Journal of STD & AIDS or Sexual Health." Dr. Aubé went on to say, "This small, but important study will also allow us to begin manufacturing Earth Science Pharmaceutical's MSN-2 medical device and will provide the molecular diagnostic expertise that we need to market our MSN-2 device in all countries. I believe this data will be the final proof that our easy method for the self-collection of vaginal specimens is accurate for the diagnosis of Gonorrhea."